Polyurethane calcification and associated thrombosis remain major obstacles hindering the long term use of polyurethanes in prosthetic valves and ventricular assist systems. Progress in the past three years of this Program has successfully addressed the initial goals of this Program by elucidating the mechanisms of polyurethane calcification and creating synthetic methodology involving hard segment activation to modify (either in bulk or on the surface) already polymerized polyurethanes. Thus, we have created polyurethanes with covalently attached bisphosphonates as effective anticalcification agents. In the Program Continuation, we will address inhibiting thrombus deposition on polyurethane, and thrombus related calcification Aim 1. To derivatize polyurethane with heparin in order to confer relative thrombo-resistance. It is hypothesized that this modification will both reduce platelet-fibrin thrombus build up and retard the development of thrombus associated calcification.
Aim 2. Polyurethanes modified with tethered gene vectors to provide local fibrinolysis.
This aim will be concerned with modifying the polyurethane surfaces to enable gene transfer of an antibody immobilize gene vector encoding for tissue plasminogen activator (tPA), in order to bring about local fibrinolysis. It is hypothesized that fibrinolysis will help to reduce thrombus buildup.
Aim 3. Semilunar cusp replacements combining bisphosphonate, heparin, and local gene therapy to over-express tPA. It is hypothesized that our combined therapeutic modifications to prevent polyurethane cuspal calcification and retard thrombosis, will provide optimal pharmacologic synergy in a sheep pulmonary cusp implant model of polyurethane calcification.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Surgery and Bioengineering Study Section (SB)
Program Officer
Lundberg, Martha
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Children's Hospital of Philadelphia
United States
Zip Code
Stachelek, Stanley J; Alferiev, Ivan; Fulmer, James et al. (2007) Biological stability of polyurethane modified with covalent attachment of di-tert-butyl-phenol. J Biomed Mater Res A 82:1004-11
Alferiev, Ivan S; Connolly, Jeanne M; Stachelek, Stanley J et al. (2006) Surface heparinization of polyurethane via bromoalkylation of hard segment nitrogens. Biomacromolecules 7:317-22
Stachelek, Stanley J; Alferiev, Ivan; Connolly, Jeanne M et al. (2006) Cholesterol-modified polyurethane valve cusps demonstrate blood outgrowth endothelial cell adhesion post-seeding in vitro and in vivo. Ann Thorac Surg 81:47-55
Stachelek, Stanley J; Alferiev, Ivan; Choi, Hoon et al. (2006) Prevention of oxidative degradation of polyurethane by covalent attachment of di-tert-butylphenol residues. J Biomed Mater Res A 78:653-61
Stachelek, Stanley J; Alferiev, Ivan; Choi, Hoon et al. (2005) Cholesterol-derivatized polyurethane: characterization and endothelial cell adhesion. J Biomed Mater Res A 72:200-12
Fishbein, Ilia; Stachelek, Stanley J; Connolly, Jeanne M et al. (2005) Site specific gene delivery in the cardiovascular system. J Control Release 109:37-48
Stachelek, S J; Song, C; Alferiev, I et al. (2004) Localized gene delivery using antibody tethered adenovirus from polyurethane heart valve cusps and intra-aortic implants. Gene Ther 11:15-24
Alferiev, Ivan; Stachelek, Stanley J; Lu, Zhibin et al. (2003) Prevention of polyurethane valve cusp calcification with covalently attached bisphosphonate diethylamino moieties. J Biomed Mater Res A 66:385-95
Alferiev, I; Vyavahare, N; Song, C et al. (2001) Bisphosphonate derivatized polyurethanes resist calcification. Biomaterials 22:2683-93
Alferiev, I S; Hinson, J T; Ogle, M et al. (2001) High reactivity of alkyl sulfides towards epoxides under conditions of collagen fixation--a convenient approach to 2-amino-4-butyrolactones. Biomaterials 22:2501-6